Switching From Mounjaro to the Wegovy Pill: UK Guide

Switching from Mounjaro to the Wegovy pill is a question many patients and clinicians are now considering as oral semaglutide becomes available in the UK. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist given by weekly injection, while the Wegovy pill contains semaglutide, a GLP-1 receptor agonist taken once daily. These are distinct medicines with different pharmacological profiles, dosing schedules, and administration requirements. There is no approved dose-for-dose conversion between them, and the transition requires individual clinical assessment rather than a simple online calculation.

Can You Switch From Mounjaro to the Wegovy Pill?

Switching is potentially possible but requires prescriber guidance, as there is no approved UK dose conversion between tirzepatide (Mounjaro) and oral semaglutide (Wegovy pill), and the two medicines have different mechanisms and dosing schedules.

It may be possible to switch from Mounjaro to the Wegovy pill, but there is no simple dose-for-dose conversion between the two medicines. Mounjaro contains tirzepatide, while Wegovy tablets contain semaglutide. They both affect appetite-regulating hormone pathways, but they are different active substances with different dosing schedules and pharmacological profiles.

Mounjaro is a long-acting GIP and GLP-1 receptor agonist given as a once-weekly injection. The Wegovy pill contains semaglutide, a GLP-1 receptor agonist, and is taken once daily. A person moving between them is therefore not simply changing from an injectable version of a medicine to a tablet version of the same medicine.

Current UK prescribing information does not provide a universal conversion table showing which Mounjaro dose corresponds to which Wegovy tablet strength. For example, none of the following should be assumed:

• 2.5 mg Mounjaro = 1.5 mg Wegovy tablets

• 5 mg Mounjaro = 4 mg Wegovy tablets

• 10 mg Mounjaro = 9 mg Wegovy tablets

• 15 mg Mounjaro = 25 mg Wegovy tablets

These would be invented comparisons rather than approved conversions.

Mounjaro is available in weekly strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg. Under the UK Summary of Product Characteristics (SmPC), treatment starts at 2.5 mg once weekly, increases to 5 mg after four weeks and can then be increased in 2.5 mg steps after at least four weeks at the current dose where needed. The recommended adult maintenance doses are 5 mg, 10 mg and 15 mg once weekly.^[1][2]

The Wegovy pill follows a separate daily schedule. The standard starting dose is 1.5 mg once daily, followed by 4 mg, 9 mg and 25 mg, with a minimum of one month at each dose level. The standard maintenance dose is 25 mg once daily, although the UK SmPC allows treatment to remain at the previous dose level if needed.

People switching from Mounjaro should not assume they can automatically begin with the 25 mg Wegovy pill because they were taking a high dose of tirzepatide. The Wegovy SmPC does contain a specific transition from 2.4 mg once-weekly semaglutide injections to 25 mg once-daily semaglutide tablets, but that instruction concerns two formulations of semaglutide. It should not be extended to Mounjaro, which contains tirzepatide.

The appropriate plan should therefore be determined by a qualified prescriber after reviewing the exact Mounjaro dose, treatment duration, side effects, response to treatment, other medicines and reason for switching.

How Long Should You Wait Between Mounjaro and the Wegovy Pill?

No single universal waiting period exists; tirzepatide has an approximately five-day half-life, so a prescriber should set an individual start date based on the last injection date and overall clinical situation.

There is no single universal waiting period that every patient should use when switching from Mounjaro to the Wegovy pill. Current UK product information does not provide a standard instruction such as "wait exactly seven days" or "wait two weeks" when changing from tirzepatide to oral semaglutide.

This is important because patients may see simple switching schedules online that appear precise but are not taken from an approved Mounjaro-to-Wegovy-tablet conversion in the UK prescribing information.

Tirzepatide remains in the body after the final Mounjaro injection. The UK Mounjaro SmPC reports an elimination half-life of approximately five days, which supports its once-weekly dosing schedule.^[2][7] A five-day half-life does not mean that all tirzepatide has disappeared after five days. Drug levels decline progressively over time.

This is one reason the timing of a switch needs clinical consideration. Starting another medicine acting on the GLP-1 pathway too aggressively may increase the potential for overlapping effects, including gastrointestinal symptoms. Conversely, creating an unnecessarily long treatment gap may disrupt appetite control, blood glucose management or weight-management progress.

The correct plan may depend on factors including:

• the current Mounjaro dose

• the date of the last injection

• how long the patient has used tirzepatide

• whether the current dose was well tolerated

• recent nausea, vomiting or diarrhoea

• whether treatment has already been interrupted

• whether Mounjaro is being used in a patient with type 2 diabetes

• other glucose-lowering medicines

• previous experience with semaglutide

• the clinical reason for changing treatment

For example, someone established on 15 mg Mounjaro for many months is in a different clinical situation from someone who has taken only four doses of 2.5 mg. Likewise, a patient stopping because of severe gastrointestinal symptoms may require a different assessment from someone switching primarily because they prefer a needle-free treatment.

Patients should not overlap Mounjaro and Wegovy on their own. The Wegovy tablet SmPC states, for patients with type 2 diabetes, that semaglutide should not be used in combination with other GLP-1 receptor agonist products. Tirzepatide acts at both GIP and GLP-1 receptors, making concurrent treatment something that should not be improvised outside a prescribed plan.

A prescriber may therefore give an individual start date for the Wegovy pill based on the last Mounjaro injection and the overall clinical situation. The absence of one universal interval is not a reason to guess. It is a reason to use a patient-specific transition plan.

The same principle applies if someone has already missed Mounjaro injections. They should tell the prescriber when the last dose was actually taken rather than simply reporting the date on which it was scheduled. Accurate timing helps the clinician understand the likely recent treatment exposure.

What Wegovy Pill Dose Do You Start After Mounjaro?

The standard UK starting dose for the Wegovy pill is 1.5 mg once daily, escalating through 4 mg, 9 mg, and 25 mg; no approved rule allows patients to skip stages based on their previous Mounjaro dose.

There is no approved rule stating that a particular Mounjaro dose converts to a particular Wegovy pill dose. Patients should not calculate their starting dose using the number of milligrams in their Mounjaro injection.

The standard UK Wegovy tablet schedule is:

• 1.5 mg once daily for at least one month

• 4 mg once daily for at least one month

• 9 mg once daily for at least one month

• 25 mg once daily as the standard maintenance dose

The UK SmPC says the starting dose for orally administered semaglutide is 1.5 mg once daily and that escalation should proceed through the listed dose steps, with a minimum duration of one month at each level. If needed, treatment can remain at the previous dose level.

However, a person moving from Mounjaro has an existing treatment history with a different incretin-based medicine. This is why the switch should be assessed individually rather than reduced to a generic online conversion chart. Patients should follow the exact strength selected by their prescriber and should not independently skip stages or begin at 25 mg because they previously tolerated high-dose Mounjaro.

The specific UK rule allowing a transition from 2.4 mg weekly injected semaglutide to 25 mg daily oral semaglutide does not establish a similar rule for tirzepatide. Someone taking 15 mg Mounjaro should not use that semaglutide-to-semaglutide transition as evidence that they can automatically begin 25 mg tablets.

Once prescribed, the Wegovy pill also requires a substantially different routine from Mounjaro. Mounjaro is injected once weekly and can be administered at any time of day, with or without meals. Wegovy tablets should be taken once daily on an empty stomach after fasting for at least 8 hours.

The tablet should be:

• swallowed whole

• taken with a small amount of plain water, up to 120 mL

• followed by a wait of at least 30 minutes before eating

• followed by a wait of at least 30 minutes before drinking

• followed by a wait of at least 30 minutes before taking other oral medicines

The tablet should not be split, crushed or chewed. Wegovy should also be taken as one tablet per day only. Patients should not combine several lower-strength tablets to imitate a prescribed higher dose.

This practical change can be significant. Someone accustomed to a weekly injection may initially assume that taking a pill is automatically easier. In reality, a daily medicine with strict fasting and timing requirements may demand more routine.

If a Wegovy tablet dose is missed, the UK SmPC says the missed dose should be skipped and the next dose taken the following day.^[3][15] Patients should not take an extra tablet to compensate.

Anyone taking other important morning medicines should discuss timing with a prescriber or pharmacist. This is particularly relevant where another medicine also has strict administration requirements.

The safest answer to "What dose of Wegovy pill should I take after Mounjaro?" is therefore that there is no universal Mounjaro-to-Wegovy conversion. The prescribed starting point should reflect the individual's treatment history and clinical assessment.

What to Expect When Changing From Mounjaro to Oral Wegovy

Appetite suppression, weight response, and gastrointestinal side effects may differ after switching, as tirzepatide and semaglutide are pharmacologically distinct; patients with type 2 diabetes should have their full treatment plan reviewed.

A patient may notice differences after changing from Mounjaro to the Wegovy pill because the medicines are not pharmacologically identical. Mounjaro contains tirzepatide, which acts at both GIP and GLP-1 receptors, while Wegovy contains semaglutide, which acts as a GLP-1 receptor agonist.^[1][7]

Both medicines can reduce appetite and support weight management, but a person's response to one does not guarantee an identical response to the other. Appetite suppression, feelings of fullness, food cravings, weight change and side effects may differ after switching.

Patients should also be cautious about comparing headline weight-loss percentages from separate clinical trials. Results from Mounjaro studies and results from trials of oral Wegovy were produced in different study populations and under different protocols. They should not be treated as though participants were directly randomised between Mounjaro and the Wegovy pill in one simple comparison.

One of the most common reasons for concern during a switch is gastrointestinal tolerability. Both tirzepatide and semaglutide can cause problems such as:

• nausea

• diarrhoea

• constipation

• vomiting

• abdominal discomfort

Switching to a tablet does not guarantee that these effects will disappear. The route of administration changes, but semaglutide still acts systemically after absorption. Patients experiencing severe or persistent symptoms should speak to a healthcare professional rather than repeatedly changing doses themselves.

Vomiting and diarrhoea can cause dehydration, which is particularly important for people with kidney problems. Severe, persistent abdominal pain requires urgent medical assessment, including consideration of acute pancreatitis.

People with type 2 diabetes need additional care when changing treatment. Both medicines can affect blood glucose. If a patient also uses insulin or a sulfonylurea, the overall treatment plan may need review because of the potential risk of hypoglycaemia. Blood glucose response should not be assumed to remain unchanged after moving from tirzepatide to semaglutide.

Pregnancy planning is also important. Neither treatment should be used during pregnancy. UK prescribing information advises discontinuing tirzepatide at least one month before a planned pregnancy.^[1][7] For semaglutide, the advised interval is at least two months before a planned pregnancy because of its long half-life.^[3][8]

There may be practical reasons to consider a switch. The Wegovy pill may appeal to someone who:

• has significant needle anxiety

• dislikes using injection pens

• prefers an oral medicine

• can consistently follow the fasting and 30-minute timing rules

Mounjaro may remain more practical for someone who:

• prefers once-weekly rather than once-daily treatment

• finds the 8-hour fasting requirement difficult

• takes several oral medicines in the morning

• is comfortable with injections

• is responding well to tirzepatide and has no strong reason to change

A switch may also be considered because of side effects, treatment availability, individual clinical response or other circumstances, but changing medicine should not be based solely on the assumption that the Wegovy pill is automatically weaker, stronger or safer.

In summary, switching from Mounjaro to the Wegovy pill may be possible, but there is no standard UK dose conversion between tirzepatide and oral semaglutide. Mounjaro doses should not be matched mathematically to 1.5 mg, 4 mg, 9 mg or 25 mg Wegovy tablets, and current product information does not provide one universal waiting period for every patient.

A qualified prescriber should plan the transition using the current Mounjaro dose, date of the last injection, treatment duration, tolerability, other medicines, diabetes status and reason for switching. Patients should not overlap treatments, select their own Wegovy starting dose or use an unofficial conversion chart without clinical guidance.

Scientific References

1. Mounjaro KwikPen 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
2. Mounjaro KwikPen 10 mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
3. Wegovy 1.5 mg tablets – Summary of Product Characteristics (SmPC).
4. Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
5. First GLP-1 tablet for weight loss approved in the UK.
6. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
7. Mounjaro: EPAR product information (tirzepatide).
8. Wegovy: EPAR product information (semaglutide).
9. Tirzepatide for managing overweight and obesity (TA1026).
10. Tirzepatide – British National Formulary (BNF).
11. Semaglutide – British National Formulary (BNF).
12. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
13. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
14. GLP-1 medicines for weight loss and diabetes: what you need to know.
15. Semaglutide: a medicine to manage type 2 diabetes or treat obesity.
16. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide.
17. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.

Frequently Asked Questions